Back to search results

Dupixent for Post-Burn Itching

This study is testing if Dupixent (dupilumab) can help adults who have ongoing itching (pruritus) after a burn injury, even after trying standard treatments. Researchers want to see if Dupixent works better than a placebo (an inactive substance) to reduce itch severity. You might be able to join if you are between 18 and 60 years old and have persistent itching from a burn scar that required grafting. The main goal is to measure changes in your itch severity after 12 weeks of treatment. The study is currently unclear on its recruitment status, but plans to enroll 46 participants.

Study design
This interventional study plans to enroll 46 participants. It compares Dupixent to a placebo.
What's involved
You would receive injections every two weeks and complete questionnaires about your itch, quality of life, and pain. Your participation would last for 13 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your itch severity will be measured at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06226610

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

Recruiting
PHASE2Ages 18–60InterventionalTreatment
Akron Children's Hospital
~46 participants
Updated 2025-09-19 on ClinicalTrials.gov
What's tested:DupilumabPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Itch Severity Scale (ISS) Scores
Measured over 12 WEEKS

Conditions

Pruritis

Explore related trials

Pruritus

Where it's being run

1 sites across 1 states
Ohio1

Who to contact

ANJAY KHANDELWAL, MD
[email protected]
330-543-4649
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Currently taking Dupixent for any other diagnosis
known allergy to Dupixent
pregnant and or lactating mothers
anyone treated for pruritus using laser therapy
currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
Currently taking steroids
persons with developmental delays or otherwise unable to complete measures
prisoners or anyone otherwise unable to give their own consent or who is not their own guardian
one or more of the following existing disorders: conjunctivitis; any co-existing dermatological condition except burns; any type of cancer; requiring dialysis; chronic Stage 3 or higher kidney disease; biliary disorder; gall bladder disorder; or another renal or hepatic disorder which, in the opinion of study physician, deems this study inappropriate for an eligible individual.
Persons unable to provide their own consent, including prisoners when their incarcerated status is not itself the focus of study, are routinely excluded from clinical trials at this site
We further exclude persons with other dermatological conditions (other than burn) , which may have pruritis or pain associated with them and who may be treated with medications other than Dupixent, and whose perceived benefit could confound our results.
We similarly exclude anyone treated for pruritis by laser therapy as their perceived benefit could confound our results.

What this trial measures

  • Itch Severity Scale (ISS) Scores12 WEEKS

    Participants' Itch Severity Scale (ISS) scores will decrease more than 2.0 points after 12 weeks following initiating use of Dupixent